{"id":"lyn-005","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal discomfort"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LYN-005 is a novel drug delivery platform technology developed by Lyndra that uses a capsule that expands and lodges in the stomach, enabling extended release of therapeutic agents over days or weeks. This approach aims to improve drug bioavailability, reduce dosing frequency, and enhance patient compliance for oral medications that would otherwise require frequent dosing or have poor absorption.","oneSentence":"LYN-005 is a gastric-resident capsule designed to deliver oral medications in a controlled, prolonged manner within the stomach.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:55.270Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oral drug delivery platform for various therapeutic payloads (specific indication dependent on loaded drug)"}]},"trialDetails":[{"nctId":"NCT06878833","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder","status":"WITHDRAWN","sponsor":"Lyndra Inc.","startDate":"2025-04-18","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""},{"nctId":"NCT05779241","phase":"PHASE3","title":"Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005","status":"COMPLETED","sponsor":"Lyndra Inc.","startDate":"2023-04-13","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":83},{"nctId":"NCT04567524","phase":"PHASE2","title":"A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules","status":"COMPLETED","sponsor":"Lyndra Inc.","startDate":"2020-08-13","conditions":"Schizophrenia Schizoaffective","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Risperidone"],"phase":"phase_3","status":"active","brandName":"LYN-005","genericName":"LYN-005","companyName":"Lyndra Inc.","companyId":"lyndra-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LYN-005 is a gastric-resident capsule designed to deliver oral medications in a controlled, prolonged manner within the stomach. Used for Oral drug delivery platform for various therapeutic payloads (specific indication dependent on loaded drug).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}